BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol 2014;32:631-42. [DOI: 10.1007/s00345-014-1293-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Antonelli A, Furlan M, Sodano M, Cindolo L, Belotti S, Tardanico R, Cozzoli A, Zanotelli T, Simeone C. Features, risk factors and clinical outcome of “very late” recurrences after surgery for localized renal carcinoma: A retrospective evaluation of a cohort with a minimum of 10 years of follow up. Int J Urol 2016;23:36-40. [DOI: 10.1111/iju.12962] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
2 Jang WS, Kim MS, Jeong WS, Chang KD, Cho KS, Ham WS, Rha KH, Hong SJ, Choi YD. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int 2018;121:225-31. [DOI: 10.1111/bju.13992] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
3 Kim DY, Karam JA. For the RECORD, we should SWITCH our treatment AXIS before the SUNRISES and TARGET the BEST treatments before INTORSECTing with a GOLD METEOR: a tale of sequences and combinations. Eur Urol 2015;67:111-3. [PMID: 24953406 DOI: 10.1016/j.eururo.2014.06.007] [Reference Citation Analysis]
4 Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016;34:1081-1086. [PMID: 26847337 DOI: 10.1007/s00345-016-1773-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 15.3] [Reference Citation Analysis]
5 Krishnamurthy A, Deen S, Ramshankar V, Majhi U. Palliative thyroidectomy in the setting of a metastatic renal cell carcinoma. Indian J Nucl Med 2014;29:273-5. [PMID: 25400374 DOI: 10.4103/0972-3919.142646] [Reference Citation Analysis]
6 Bharthuar A, Pandey H, Sood S. Management of metastatic renal cell carcinoma - mini review. J Kidney Cancer VHL 2015;2:75-83. [PMID: 28326262 DOI: 10.15586/jkcvhl.2015.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Yoshida S, Takahara T, Arita Y, Sakaino S, Katahira K, Fujii Y. Whole‐body diffusion‐weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond. Int J Urol 2021;28:502-13. [DOI: 10.1111/iju.14497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Stevens DJ, Sooriakumaran P. Oligometastatic Prostate Cancer. Curr Treat Options Oncol 2016;17:62. [PMID: 27787754 DOI: 10.1007/s11864-016-0439-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
9 Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894-906. [PMID: 26318520 DOI: 10.1016/s0140-6736(15)00046-x] [Cited by in Crossref: 360] [Cited by in F6Publishing: 208] [Article Influence: 51.4] [Reference Citation Analysis]
10 Fares AF, Araujo DV, Calsavara V, Saito AO, Formiga MN, Dettino AA, Zequi S, da Costa WH, Cunha IW. Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model. Ecancermedicalscience 2019;13:967. [PMID: 31921338 DOI: 10.3332/ecancer.2019.967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 You D, Lee C, Jeong IG, Song C, Lee JL, Hong B, Hong JH, Ahn H, Kim CS. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2016;142:2331-8. [PMID: 27553579 DOI: 10.1007/s00432-016-2217-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
12 Gravis G, Chanez B, Derosa L, Beuselinck B, Barthelemy P, Laguerre B, Brachet PE, Joly F, Escudier B, Harrison DJ. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urol Oncol. 2016;34:167.e17-167.e23. [PMID: 26670200 DOI: 10.1016/j.urolonc.2015.10.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
13 Pal SK, Bergerot P, Figlin RA. Renal cell carcinoma: An update for the practicing urologist. Asian J Urol 2015;2:19-25. [PMID: 29264115 DOI: 10.1016/j.ajur.2015.04.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
14 Tonyali S, Yazici S. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies? Int Urol Nephrol 2016;48:671-80. [DOI: 10.1007/s11255-016-1226-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
15 Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, Trinh QD, Choueiri TK. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. Eur J Surg Oncol. 2018;44:1439-1445. [PMID: 29935840 DOI: 10.1016/j.ejso.2018.05.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
16 Martel G, Bertens KA, Canil C. Surgical Management of Genitourinary Cancer Liver Metastases. Surg Oncol Clin N Am 2021;30:89-102. [PMID: 33220811 DOI: 10.1016/j.soc.2020.08.003] [Reference Citation Analysis]
17 Pikoulis E, Margonis GA, Antoniou E. Surgical Management of Renal Cell Cancer Liver Metastases. Scand J Surg 2016;105:263-8. [PMID: 26929295 DOI: 10.1177/1457496916630644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Magdy A, Bretterbauer K, Hruby S, Kunit T, Colleselli D, Janetschek G, Mitterberger M. 28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC. Case Rep Urol 2015;2015:523258. [PMID: 25810943 DOI: 10.1155/2015/523258] [Reference Citation Analysis]
19 Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Dzyuba-Negrean C, Shariat SF, Saad F, Simeone C, Berruti A, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI. Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:e730-8. [PMID: 32800473 DOI: 10.1016/j.clgc.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E, Mistretta FA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. Int Urol Nephrol 2019;51:2181-8. [PMID: 31468289 DOI: 10.1007/s11255-019-02266-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bettenhausen A, Hamaji M, Burt BM, Ali SO. Pleurectomy and decortication for metastatic renal cell carcinoma. J Thorac Cardiovasc Surg 2015;150:e3-5. [PMID: 26126480 DOI: 10.1016/j.jtcvs.2015.05.007] [Reference Citation Analysis]
22 Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M, Briganti A. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852-863. [PMID: 25240974 DOI: 10.1016/j.eururo.2014.09.004] [Cited by in Crossref: 226] [Cited by in F6Publishing: 203] [Article Influence: 28.3] [Reference Citation Analysis]
23 Wu JX, Lin LM, He JY, Hong L, Li JL. Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study. Medicine (Baltimore) 2016;95:e2789. [PMID: 26871838 DOI: 10.1097/MD.0000000000002789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
24 Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol 2020;17:168-82. [PMID: 31712648 DOI: 10.1038/s41571-019-0284-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
25 Merseburger A, Kuczyk M, Haverich A, Krüger M. Metastasenchirurgie beim Nierenzellkarzinom. Onkologe 2015;21:28-34. [DOI: 10.1007/s00761-014-2775-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Hau HM, Thalmann F, Lübbert C, Morgul MH, Schmelzle M, Atanasov G, Benzing C, Lange U, Ascherl R, Ganzer R, Uhlmann D, Tautenhahn HM, Wiltberger G, Bartels M. The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy. BMC Surg 2016;16:49. [PMID: 27444582 DOI: 10.1186/s12893-016-0163-0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada. Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Can Urol Assoc J 2019;13:343-54. [PMID: 31603413 DOI: 10.5489/cuaj.6256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
28 Saarela O, Liu ZA. A flexible parametric approach for estimating continuous-time inverse probability of treatment and censoring weights: A flexible parametric approach for estimating continuous-time inverse probability of treatment and censoring weights. Statist Med 2016;35:4238-51. [DOI: 10.1002/sim.6979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada. Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Can Urol Assoc J 2017;11:310-20. [PMID: 29382441 DOI: 10.5489/cuaj.4769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
30 Donini M, Buti S, Massari F, Mollica V, Rizzo A, Montironi R, Bersanelli M, Santoni M. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert Rev Anticancer Ther 2020;20:491-501. [PMID: 32479120 DOI: 10.1080/14737140.2020.1770601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
31 Canil C, Kapoor A, Basappa NS, Bjarnason G, Bossé D, Dudani S, Graham J, Gray S, Hansen AR, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Thana M, Winquist E, Wood LA, Reaume MN, Maloni R, Hotte SJ; Kidney Cancer Research Network of Canada. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Can Urol Assoc J 2021;15:84-97. [PMID: 33830005 DOI: 10.5489/cuaj.7245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Puente Vázquez J, Alonso Gordoa T, Moreno J, Poma L, Diaz Rubio E, Gomez A, Blazquez J, Gonzalez Larriba JL. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies. Curr Treat Options in Oncol 2015;16. [DOI: 10.1007/s11864-015-0337-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
33 Hamner JB, Raoof M, Dumitra S, Schoellhammer HF, Crowder C, Ituarte PH, Kim J, Singh G. Evolving Role of Hepatic Resection for Metastatic Urologic Malignancies. The American Surgeon 2017;83:628-32. [DOI: 10.1177/000313481708300629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Ulukan B, Bihorac A, Sipahioglu T, Kiraly R, Fesus L, Telci D. Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression. ACS Omega 2020;5:28273-84. [PMID: 33163811 DOI: 10.1021/acsomega.0c04226] [Reference Citation Analysis]
35 Barboza MP, Speir RW, Boris RS, Calaway AC, Cary C, Foster RS, Masterson TA. Understanding the role of salvage lymphadenectomy in node only recurrences after nephrectomy for renal cell carcinoma. Urol Oncol 2020;38:739.e1-8. [PMID: 32646691 DOI: 10.1016/j.urolonc.2020.06.006] [Reference Citation Analysis]
36 Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ. Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2015;13:e159-66. [DOI: 10.1016/j.clgc.2014.12.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]